What are the unique benefits of Phage Display for ADC antibody discovery?

Phage Display is uniquely suited for ADC development because it allows for directed selection under highly controlled in vitro conditions. Unlike hybridoma techniques, we can: Target Specific Epitopes: Use competitive elution to find antibodies that bind to internalizing-prone domains. High Throughput: Screen libraries of 10^11 diversity to identify rare clones with the perfect balance of affinity and stability. Human Sequences: Our premade libraries consist of fully human scFv or Fab frameworks, reducing the risk of immunogenicity in patients.

How do you identify antibodies with high internalization rates using Phage Display?

Internalization is the "make-or-break" factor for ADCs. We employ a specialized Cell-Based Internalization Panning strategy: Internalization Round: Phage candidates are incubated with target-positive cells at 37°C to allow for receptor-mediated endocytosis. Surface Stripping: We use a low-pH wash to remove non-internalized phages from the cell surface. Intracellular Recovery: Only the phages that have been successfully internalized are recovered from the cell lysate and amplified for the next round, ensuring the enrichment of high-efficiency ADC carriers.

How do you ensure the stability of scFv or Fab fragments from the library?

ADC conjugation and systemic circulation require highly stable antibody scaffolds. We incorporate a "Pre-selection" step in our phage workflow: Thermostability Pressure: Exposing the phage library to elevated temperatures or protease treatment before panning to eliminate unstable or aggregation-prone clones. Sequence Liabilities: Screening out sequences with potential post-translational modification (PTM) sites (e.g., deamidation, isomerization) that could affect the ADC's shelf-life.

Can you screen for cross-reactivity with Non-Human Primates (NHP) using Phage Display?

Yes. To streamline your IND-enabling studies, we perform Cross-species Panning. We alternate selection rounds between the human target and the Cynomolgus monkey ortholog. This ensures the resulting lead candidate can be used in both efficacy and safety/toxicology models without the need for a surrogate antibody.

ADC Therapy Discovery Service by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

Creative Biolabs accelerates your ADC program by bypassing animal immunization. We deploy massive premade human antibody libraries and specialized screening strategies to isolate high-affinity candidates. Our process ensures these antibodies not only recognize your target but also facilitate rapid internalization for precise cytotoxic payload delivery.

Request a Sample Report + Pricing

Antibody Discovery for ADC Therapy

In ADC development, binding is only the beginning. The ADC Paradox often presents a challenge: high-affinity binders may fail to internalize, or internalize without reaching the lysosome. Furthermore, the antibody must remain stable once conjugated to hydrophobic payloads. Creative Biolabs solves this at the source. We combine our massive premade human libraries with Internalization-First screening. We don't just look for binders; we filter for carriers, which are antibodies that bind specifically, internalize rapidly, and possess the biophysical robustness required for conjugation chemistry.

At Creative Biolabs, screening is a strategic filter for therapeutic efficacy. Our phage and yeast display platforms are engineered to identify antibodies that drive receptor-mediated endocytosis. Through pH-sensitive elution strategies and cell-based internalization tests early in the funnel, we systematically eliminate surface-stuck binders. We also perform early developability triage to ensure your candidates have clean hydrophobicity profiles, preventing aggregation catastrophic to ADC formulation.

Endocytosis-Driven Selection
Screening strategies tuned to identify rapid internalizers.

High Specificity
Stringent negative selection to minimize off-target toxicity.

Conjugation-Ready Frameworks
Optimized sequences with low surface hydrophobicity.

Diverse Epitope Coverage
Access epitopes that trigger receptor clustering and uptake.

We'll Reply Within 24 Hours. Request a Quote

How We Work

Inputs

Target name, Indication, Payload class, Internalization goals.

Workflow

Fig.1 Antigen Design. (Creative Biolabs AI)

Antigen Design

Fig.2 Enrichment (Panning). (Creative Biolabs AI)

Enrichment (Panning)

Fig.3 Clone Screening. (Creative Biolabs AI)

Clone Screening

Fig.4 Functional Selection. (Creative Biolabs AI)

Functional Selection

Fig.5 Sequence Analytics. (Creative Biolabs AI)

Sequence Analytics

Fig.6 IgG Conversion. (Creative Biolabs AI)

IgG Conversion

Deliverables

Ranked internalizing binders, epitope bins, sequence families, IgG mini-panel, developability metrics.

Contact Creative Biolabs for a Custom Quote

Ready-to-Screen Antibody Libraries

We offer a curated selection of libraries optimized for finding stable, internalizing antibodies suitable for conjugation.

Human Camel Llama Alpaca Humanized V_HH

Antibody Library ID	Display Technology	Library Format	Library Size
HuScL-6 Highly Recommended	pIII-fusion, Phagemid Phage Display	Naïve scFv	2.1×10¹¹
HuScL-3S	pIII-fusion, Phagemid Phage Display	Semi-synthetic scFv	>1.0×10¹¹
HuFabL-4	pIII-fusion, Phagemid Phage Display	Naïve Fab	1.9×10¹⁰
HuFabssL-1	pIII-fusion, Phagemid Phage Display	Naïve & synthetic Fab	1.8×10¹⁰

Find the Perfect Library for Your Target

Case Study: High-Diversity Libraries, High-Impact Outcomes

Discovery of Species Cross-Reactive scFv Antibodies for Next-Generation ADC Development
Objective	In the development of ADCs for solid tumors, such as Renal Cell Carcinoma (RCC), identifying leads with cross-species reactivity is a critical success factor. To facilitate accurate safety and efficacy evaluations in non-human primates (NHP), the antibody must recognize both the human antigen and its Cynomolgus/Rhesus ortholog with similar affinity. This case study demonstrates our ability to use a Premade Synthetic Human scFv Library to isolate high-affinity binders against a high-value RCC surface target, while strategically identifying clones with cross-reactive properties.
Target Analysis & Strategy	The target in this study is a key enzyme overexpressed in specific carcinomas. Bioinformatics analysis revealed a high sequence identity (>90%) between the Human and Rhesus versions of the extracellular domain. To ensure the highest affinity for the therapeutic lead while capturing species-broadening candidates, we implemented a Human-Target-Driven Selection with Parallel Identification strategy: Screening: High-stringency panning using the Human Target Protein. Selection: High-throughput monoclonal identification against both Human and Rhesus orthologs simultaneously. Validation: Dual-species validation via Phage ELISA and Soluble scFv ELISA.
Key Results	Our platform successfully identified ~10 unique human scFv clones with distinct binding profiles, providing the client with multiple options for their ADC pipeline: Cross-Reactive Candidates (50% of clones) Half of the unique clones exhibited robust, positive binding to both Human and Rhesus orthologs. These leads are ideal for programs requiring NHP-based toxicology and PK/PD studies. Human-Specific Candidates (50% of clones) The remaining clones showed exclusive specificity for the human target, serving as high-potency options for specialized therapeutic designs.
Value-Added Technical Support for ADC Programs	We go beyond providing sequences by offering integrated downstream consultancy to ensure the "developability" of the leads as ADCs: Sequence Optimization Detailed analysis of CDR regions to identify and mitigate potential liabilities (e.g., deamidation, isomerization, or glycosylation sites). Conjugation Strategy Consultation We provided technical insights into suitable conjugation chemistries for the scFv/IgG format: Payload Selection: Alignment of the antibody's internalization profile with appropriate linker-payload combinations. Site-Specific Engineering: Advice on implementing engineered cysteine residues or enzymatic tags to achieve a homogenous Drug-to-Antibody Ratio (DAR), optimizing the therapeutic index.

Have a Deadline? Get Expedited Pricing

Related Services

Fig.9 Antibody Discovery for Immunotherapy. (Creative Biolabs Authorized)

Premade Antibody Library based Antibody Discovery Service for CAR-T Therapy

Premade Antibody Library based Antibody Discovery Service for Immune Checkpoint

Why Choose Us?

Functional-First Triage

We go beyond simple binding by integrating cell-based internalization assays early in the screening process. This ensures we select candidates based on their biological ability to deliver cytotoxic payloads into the target cell, rather than just affinity alone.

Superior V_HH Scaffolds

Our premade V_HH libraries provide robust scaffolds that yield high-affinity V_HH clones. These single-domain antibodies are ideal for ADCs due to their deep tissue penetration in solid tumors and ease of engineering into multi-valent formats.

Weeks, Not Months

Our premade synthetic platform bypasses the traditional 3-4 months animal immunization phase. We compress the hit-to-lead timeline to just 8-12 weeks, allowing you to begin conjugation and cytotoxicity testing sooner.

Cross-Species Reactivity

We actively screen for human, cyno, and mouse cross-reactivity during discovery. This enables you to enter syngeneic models and toxicology studies using the same lead candidate, eliminating the need to develop separate surrogate antibodies for preclinical testing.

High Stability & Low Aggregation

ADC conjugation processes can be harsh. We prioritize candidates with high thermal stability and low aggregation propensity, ensuring the resulting ADC remains stable and effective during both manufacturing and circulation.

Site-Specific Engineering Support

From protein biotinylation to identifying optimal conjugation sites, we provide technical support to ensure your antibody leads are ADC-ready from day one.

Get a Tailored Estimate

Ready to move fast? Creative Biolabs will scope your target, advise on best library and protocol, and get screening up and running as soon as possible.

FAQ

What are the unique benefits of Phage Display for ADC antibody discovery?
Phage Display is uniquely suited for ADC development because it allows for directed selection under highly controlled in vitro conditions. Unlike hybridoma techniques, we can: Target Specific Epitopes: Use competitive elution to find antibodies that bind to internalizing-prone domains. High Throughput: Screen libraries of 10¹¹ diversity to identify rare clones with the perfect balance of affinity and stability. Human Sequences: Our premade libraries consist of fully human scFv or Fab frameworks, reducing the risk of immunogenicity in patients.
How do you identify antibodies with high internalization rates using Phage Display?
Internalization is the "make-or-break" factor for ADCs. We employ a specialized Cell-Based Internalization Panning strategy: Internalization Round: Phage candidates are incubated with target-positive cells at 37°C to allow for receptor-mediated endocytosis. Surface Stripping: We use a low-pH wash to remove non-internalized phages from the cell surface. Intracellular Recovery: Only the phages that have been successfully internalized are recovered from the cell lysate and amplified for the next round, ensuring the enrichment of high-efficiency ADC carriers.
How do you ensure the stability of scFv or Fab fragments from the library?
ADC conjugation and systemic circulation require highly stable antibody scaffolds. We incorporate a "Pre-selection" step in our phage workflow: Thermostability Pressure: Exposing the phage library to elevated temperatures or protease treatment before panning to eliminate unstable or aggregation-prone clones. Sequence Liabilities: Screening out sequences with potential post-translational modification (PTM) sites (e.g., deamidation, isomerization) that could affect the ADC's shelf-life.
Can you screen for cross-reactivity with Non-Human Primates (NHP) using Phage Display?
Yes. To streamline your IND-enabling studies, we perform Cross-species Panning. We alternate selection rounds between the human target and the Cynomolgus monkey ortholog. This ensures the resulting lead candidate can be used in both efficacy and safety/toxicology models without the need for a surrogate antibody.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: